메뉴 건너뛰기




Volumn 3, Issue 10 SUPPL. 4, 2006, Pages

Defining the role of panitumumab in colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; VECTIBIX;

EID: 33845605751     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (8)

References (27)
  • 1
    • 33750909668 scopus 로고    scopus 로고
    • A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)
    • Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 2006;24(18S):3506.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3506
    • Fuchs, C.1    Marshall, J.2    Mitchell, E.3
  • 2
    • 33749016960 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin/fluoropynmidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-study
    • Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropynmidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study. J Clin Oncol 2006;24(18S):3510.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3510
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3
  • 3
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorm, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorm, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3
  • 4
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 5
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorm tor metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorm tor metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 6
    • 0036362181 scopus 로고    scopus 로고
    • Why the epidermal growth factor receptor? The rationale for cancer therapy
    • Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 2002;7(suppl 4):2-8.
    • (2002) Oncologist , vol.7 , Issue.SUPPL. 4 , pp. 2-8
    • Baselga, J.1
  • 7
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 8
    • 0002823211 scopus 로고    scopus 로고
    • Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
    • Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:7.
    • (2001) Proc Am Soc Clin Oncol , vol.20 , pp. 7
    • Saltz, L.B.1    Rubin, M.2    Hochster, H.3
  • 9
    • 0001407135 scopus 로고    scopus 로고
    • Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
    • Saltz LB, Meropol NJ, Loehrer P, et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:504.
    • (2002) Proc Am Soc Clin Oncol , vol.21 , pp. 504
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer, P.3
  • 10
    • 24144446493 scopus 로고    scopus 로고
    • Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer
    • Lenz HJ, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16S):3536.
    • (2005) J Clin Oncol , vol.23 , Issue.16 S , pp. 3536
    • Lenz, H.J.1    Mayer, R.J.2    Mirtsching, B.3
  • 11
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity m colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity m colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
    • (2005) J Clin Oncol , vol.23 , pp. 1803-1810
    • Chung, K.Y.1    Shia, J.2    Kemeny, N.E.3
  • 12
    • 33750154102 scopus 로고    scopus 로고
    • Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data
    • Tejpar S, Peeters M, Humblet Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. J Clin Oncol 2006;24(18S):3554.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3554
    • Tejpar, S.1    Peeters, M.2    Humblet, Y.3
  • 13
    • 1342290189 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    • Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
    • (2004) J Clin Oncol , vol.22 , pp. 229-237
    • Tournigand, C.1    Andre, T.2    Achille, E.3
  • 14
    • 0037531121 scopus 로고    scopus 로고
    • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
    • Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
    • (2003) J Clin Oncol , vol.21 , pp. 2059-2069
    • Rothenberg, M.L.1    Oza, A.M.2    Bigelow, R.H.3
  • 15
    • 23844435339 scopus 로고    scopus 로고
    • Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study
    • Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005;25(16S):3535.
    • (2005) J Clin Oncol , vol.25 , Issue.16 S , pp. 3535
    • Diaz Rubio, E.1    Tabernero, J.2    Van Cutsem, E.3
  • 16
    • 33750905700 scopus 로고    scopus 로고
    • Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcmoma of the colon or rectum (MCRC): CALGB 80203 preliminary results
    • Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcmoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006;24(18S):3509.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3509
    • Venook, A.1    Niedzwiecki, D.2    Hollis, D.3
  • 17
    • 0035117355 scopus 로고    scopus 로고
    • Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
    • Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
    • (2001) Crit Rev Oncol Hematol , vol.38 , pp. 17-23
    • Yang, X.D.1    Jia, X.C.2    Corvalan, J.R.3
  • 18
    • 23844454976 scopus 로고    scopus 로고
    • Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)
    • Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005;23(16S):3520.
    • (2005) J Clin Oncol , vol.23 , Issue.16 S , pp. 3520
    • Malik, I.1    Hecht, J.R.2    Patnaik, A.3
  • 19
    • 33748994720 scopus 로고    scopus 로고
    • Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr)
    • Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006;24(18S):3548.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3548
    • Berlin, J.1    Neubauer, M.2    Swanson, P.3
  • 20
    • 33748994977 scopus 로고    scopus 로고
    • Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels ot epidermal growth factor receptor (EGFr)
    • Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels ot epidermal growth factor receptor (EGFr). J Clin Oncol 2006;24(18S):3547.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3547
    • Hecht, J.1    Mitchell, E.2    Baranda, J.3
  • 22
    • 33749030519 scopus 로고    scopus 로고
    • Branchburg, NJ: ImClone Systems Inc/Princeton, NJ: Bristol-Myers Squibb Co
    • Erbitux [package insert]. Branchburg, NJ: ImClone Systems Inc/Princeton, NJ: Bristol-Myers Squibb Co; 2006.
    • (2006) Erbitux [Package Insert]
  • 23
    • 33845624932 scopus 로고    scopus 로고
    • Thousand Oaks, Calif: Amgen Inc
    • Vectibix [package insert]. Thousand Oaks, Calif: Amgen Inc; 2006.
    • (2006) Vectibix [Package Insert]
  • 24
    • 4143050397 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    • Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-3015.
    • (2004) J Clin Oncol , vol.22 , pp. 3003-3015
    • Rowinsky, E.K.1    Schwartz, G.H.2    Gollob, J.A.3
  • 25
    • 33750017775 scopus 로고    scopus 로고
    • Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)
    • Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006;24(18S):3085.
    • (2006) J Clin Oncol , vol.24 , Issue.18 S , pp. 3085
    • Tabernero, J.1    Cervantes, A.2    Martinelli, E.3
  • 26
    • 33847694798 scopus 로고    scopus 로고
    • Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIR1 for first-line treatment of metastatic colorectal cancer (mCRC)
    • Paper presented at the; January 26-28; San Francisco, Calif. Abstract 237
    • Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIR1 for first-line treatment of metastatic colorectal cancer (mCRC). Paper presented at the 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, Calif. Abstract 237.
    • (2006) 2006 Gastrointestinal Cancers Symposium
    • Hecht, J.1    Posey, J.2    Tchekmedyian, S.3
  • 27
    • 23844555670 scopus 로고    scopus 로고
    • Cetuximab therapy and symptomatic hypomagnesemia
    • Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1221-1224
    • Schrag, D.1    Chung, K.Y.2    Flombaum, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.